A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.

Citation

• Kirkwood, J. M., Gonzalez, R., Reintgen, D. S., Clingan, P. R., McWilliams, R. R., Ilaria, R. L., . . . Millward, M. (2010). A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 28(15_suppl), 8541. doi:10.1200/jco.2010.28.15_suppl.8541

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.8541

Web Of Science Accession Number

Start Page

• 8541

End Page

• 8541

Volume

• 28

Issue

• 15_suppl

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2010

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Kirkwood, J. M., Gonzalez, R., Reintgen, D. S., Clingan, P. R., McWilliams, R. R., Ilaria, R. L., . . . Millward, M. (2010). A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 28(15_suppl), 8541. doi:10.1200/jco.2010.28.15_suppl.8541

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.8541

Web Of Science Accession Number

Start Page

• 8541

End Page

• 8541

Volume

• 28

Issue

• 15_suppl